One of the hallmarks of integrative cancer care, as defined in this journal, is a willingness to embrace useful new technologies for diagnosis and treatment of cancer. In that spirit, we present an interview with one of the users of a new radiologic diagnostic technique. The innovative software solution called 3TP is designed to provide color contrast enhancement of magnetic resonance imaging (MRI) screening, enabling radiologists to distinguish between cancerous and noncancerous tissue. As our interview with Dr Julian Safir of Nassau Radiologic Group in New York shows, this technology is already making waves in the area of breast MRIs. Developed by Dr Hadassa Degani of the Weizmann Institute of Science in Rehovot, Israel, 3TP enables rapid interpretation of contrast-enhanced MRI images. Dr Degani developed the 3TP model based on certain properties of contrast media in tissue. The new technology manipulates the image generated by magnetic resonance to measure tissue permeability and extracellular volume fraction on a pixel-by-pixel basis at 3 distinct time points. The software then assigns a color to each pixel, enabling the radiologist to rapidly identify conspicuous lesions. According to Dr Safir, the colorized images substantially improve the efficiency of interpreting MRIs and eliminate the problem of false positives, which has plagued breast MRI screening. Clinical testing in breast cancer patients has shown an exceptionally high correlation between biopsy-proven results and 3TP. Additional research with other cancers is expanding the potential scope of this important breakthrough. "The potential for 3TP to provide rapid and accurate diagnoses carries with it meaningful clinical implications," says Dr Neil Rofsky of Beth Israel Deaconess Medical Center in Boston. "These include the possibility to reduce the number of biopsies, to minimize test redundancy and to streamline the workup of our patients."
Julian Safir, MD, BSE, is a radiologist at the Nassau Radiologic Group on Long Island, New York. Dr Safir is one of the users of 3TP but has no official association with the company. He owns no stock and has no vested interest in the company.
ICT: How did you become interested in 3TP?
JS: My background is in MRI, or magnetic resonance imaging. I received a fellowship in MRI from New York University 11 years ago. At that time, breast MRI for cancer screening, detection, and staging really came into vogue. I have been doing breast MRI for cancer detection for about 10 years now. Breast MRI is innovative but it's also an accepted means of cancer detection by the American College of Radiology along with mammography and ultrasound. So it is an established technology. The problem with breast MRI, even though it's very accurate, ie, very sensitive at catching all breast cancers (almost 100%, according to the literature), is that it has a lower specificity. This is nothing new, and it's widely published. Sensitivity has always been great, but specificity has been a problem. This means that, up until now, before 3TP, the MRI picked up not only malignancy but plenty of benign things as well. There were many false positives, which led to many unnecessary biopsies. This is where 3TP primarily comes in. By the way, mammography, the x-raybased technology, has many shortcomings as well.
ICT: Please comment on some of those shortcomings of mammography and how it measures up against breast MRI exams.
JS: Not only does mammography miss cancers in a significant number of cases, especially in younger women with dense breast tissue, but it also causes a tremendous amount of unnecessary anxiety by resulting in many false positives and thus unnecessary biopsies and so on. So there was a clear need for new technologies, especially for women with dense breast tissue. (Dense breast tissue makes it very difficult, if not impossible, to see beyond to whether there's cancer within the breast.) This is where breast MRI came in. Although much more expensive than breast mammography, breast MRI does catch everything-benign as well as malignant growths. Mammography is much less expensive, and for this reason, it remains the primary screening method in the general population. It is about 10-fold cheaper than breast MRI. Mammography is an x-ray-based technology that involves radiation, whereas MRI involves no radiation whatsoever.
ICT: So where does the 3TP come in with respect to the breast MRI?
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JS: 3TP really adds to the accuracy of the MRI reading. In other words, if something looks abnormal, 3TP helps you decide whether that abnormality is significant, that is, whether it's benign or malignant. So it serves 2 functions. One is that it allows you to define what you see on the MRI as either benign or malignant, which is the most important function. It increases the specificity or accuracy of the breast MRI itself to somewhere in the 90% range, where it used to be in the 40% to 60% range. So it helps you decide whether a biopsy is needed or whether you should worry about something. It decreases anxiety. If it's benign, forget it. If suspicious, let's biopsy.
The other point about 3TP, besides increasing the accuracy of the reading, is that it allows the radiologist to read them faster. So instead of requiring half an hour per reading, the radiologist can now do it in 10 minutes. That is a significant time savings for the radiologist. This ultimately is a major cost savings to the health profession. It doesn't directly benefit the patient, but the patient does benefit from the accuracy.
ICT:
What is the 90% specificity figure based on? JS: That's based on the 3TP studies to date, including several by Dr Degani. The specificity was at least 90% for being able to identify malignancy. The sensitivity, with or without 3TP, has always been high-almost 100%. So this is really a specificity tool, an aid to the radiologist to say whether a lesion is something worth acting on or not.
Please introduce the 3TP technology as if you were speaking to a group of oncologists. JS: Again, the breast MRI is useful for women for whom mammography falls short (women with very dense breast tissue, or those carrying the BRCA1 gene-this technology is very useful for this population). 3TP allows the radiologist to categorize what he sees on the breast MRI itself using what we call enhancement kinetics. Cancers are enhanced with the dye in a certain fashion, so that tumors show up but benign lesions don't. This allows the radiologist to be more accurate in his report to the referring doctor. It allows the referring doctor to receive a more black-and-white report, one that takes away the guesswork and worry.
3TP is software, so its application comes in after the patient leaves the exam. The software automatically manipulates the image produced by the breast MRI so that cancer shows up in a very specific color-coded way. Physicians can quickly learn to use this technology, and all that is needed for viewing is a standard computer monitor.
ICT: So is this a quantum leap for MRI technology?
JS: It is a quantum leap. It's a quantum leap because the breast MRI has been around for so long, but the problems with specificity have been a very real concern for oncologists and, by implication, for the patient. This allows you to use the MRI technology with much greater accuracy.
ICT:
Will 3TP or similar technologies ever pose any threat to mammography? JS: No, the NCI [National Cancer Institute] still recommends mammography as the major screening technique for the population. That may change in the future with reimbursements and cost changes, but I want to make it very clear that breast MRI is not about to replace mammography in the general population. Where it is replacing mammography is in certain segments of the population, such as women with high-risk genes, or dense breast tissue, or breast implants-all of those women do not benefit from mammography.
ICT: Is there any indication that the cost of breast MRIs will drop in the near future?
JS: This should eventually happen, though there's no way to tell when that will be. As the volume and demand for breast MRI increases, more resources and more dedicated equipment for breast MRI will become available, and thus the cost of the exam is likely to drop substantially over time. Remember that breast MRI is done on a general MRI machine that does many other parts of the body. Companies are now working on making dedicated breast MRI machines.
ICT: Has the false-positive factor with breast MRI reduced the physician's desire to resort to the breast MRI and to instead rely on palpation and other methods of detection? JS: Most definitely. There has definitely been reluctance because of the relatively high rate of false positives and because of the cost, although insurance companies are covering breast MRIs for specific indications. The 3TP will save insurance companies by avoiding false positives and therefore avoiding many unnecessary costs in terms of biopsies and follow-ups, so the overall cost is greatly contained by 3TP. Insurance companies may be willing to provide even broader coverage now that the specificity is better. ICT: Are there other cancers that this technology will apply to? working on ascertaining its value for detection of prostate cancer. After that, they are planning to investigate its usefulness for detection of lung cancer and ovarian cancer. This is all in the research domain.
ICT: So cancers that have a long latency, such as cancers of the lung, pancreas, colon, and ovaries, might be picked up earlier with 3TP.
JS: If the research shows that MRI technology combined with 3TP is effective for detecting these cancers at earlier stages, then this combination may in time become part of screening technologies for these cancers, once cost issues are resolved.
